A systematic review about the epidemiology of primary progressive multiple sclerosis in Latin America and the Caribbean

Rojas, Juan Ignacio; Romano, Marina; Patrucco, Liliana; Cristiano, Edgardo

doi:10.1016/j.msard.2018.02.024

Cited by 13 publications

(7 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…28 A similar prevalence rate (13.9%) was reported in the New Zealand MS prevalence study but a lower rate (10.2%) was recorded in the Tasmanian MS Prevalence & Genetics Study. 28 We assumed that 14% of the estimated 31,650 people with MS had PPMS in 2018 (4,430 people) [4][5][6][7][8] and that there was an equal number (2,215) of males and females with PPMS. 4,12,29,30 The age-sex distribution of Australians with MS was estimated by averaging the percentage distributions reported in the 2015 SDAC and the AMSLS population described in Taylor et al, 28 for males and females ( Table 3).…”

Section: Ppms Population In Australiamentioning

confidence: 99%

“…PPMS occurs in 10-15% people with MS. [4][5][6][7][8] It is characterized by a progressive course of disability with continuous neurological worsening from the first onset of symptoms, without distinct relapses followed by complete or partial remission. [9][10][11] PPMS is associated with older age at onset, affects men and women equally, and has considerably more rapid disease progression relative to the more prevalent RRMS.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Societal costs of primary progressive multiple sclerosis in Australia and the economic impact of a hypothetical disease-modifying treatment that could delay disease progression

Brown

Brunner³

et al. 2021

Journal of Medical Economics

View full text Add to dashboard Cite

Aims: Primary progressive multiple sclerosis (PPMS) has a progressive course of disability with continuous neurological worsening. We investigated societal costs of PPMS in Australia and the economic impact of increasing the independence of people with PPMS through delaying disease progression. Methods: This prevalence-based retrospective cost-of-illness analysis used observational data from publicly available secondary data sources and literature findings. Direct and indirect costs of PPMS were considered. A replica estimated population was created using the National Centre for Social and Economic Modelling (NATSEM) microsimulation model of the Australian tax and transfer system (STINMODþ). Using a budget impact analysis approach, we modelled the effect on PPMS costs of an effective hypothetical disease-modifying treatment (DMT) that delays disease progression by a year from mild to moderate and a further year from moderate to severe PPMS. Results: An estimated 31,650 Australians have multiple sclerosis (MS) including 4,430 with PPMS. The proportion with PPMS was estimated to increase with age and disease severity. Overall 25% of males with MS, and 10% of females, were estimated to have PPMS. Societal cost of PPMS in Australia in 2018 was estimated at AU$418.1 million. Indirect costs contributed 67.5% of total costs, attributable to reduced workforce participation and need for informal care. The modelled DMT was estimated to create savings of AU$14.9 million (3.6%). Fewer people had moderate and severe PPMS resulting in major cost savings, partially offset by increased costs of treatment, care and support for a relative increase in the number of people with mild PPMS and their increased productivity losses. Limitations: Publicly available data may be incomplete. The potential cost of the DMT was not considered. Conclusions: The economic burden of PPMS was estimated at AU$418 million in 2018. An effective DMT that delayed progression from disease severity states by one year could provide significant cost savings.

show abstract

Section: Ppms Population In Australiamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Societal costs of primary progressive multiple sclerosis in Australia and the economic impact of a hypothetical disease-modifying treatment that could delay disease progression

Brown

Brunner³

et al. 2021

Journal of Medical Economics

View full text Add to dashboard Cite

show abstract

“…In a consensus paper, Lublin et al revised the definitions of the clinical course of MS by using refined descriptors that include consideration of disease activity and encourage differentiation between the relapsing and progressive forms of MS, but they also acknowledged that to date, there are no clear clinical, imaging, immunologic, or pathologic criteria to determine the transition point when RRMS converts to SPMS and that the transition is usually gradual [ 2 ]. With more clarity on the MS disease classification, researchers are currently attempting to explore epidemiological aspects by MS subtype [ 2 , 8 ]. Khurana et al reported a wide variation in the estimated prevalence of SPMS within and across countries but with uncertainty related to methodology and consequent results [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Systematic literature review and meta-analysis of the prevalence of secondary progressive multiple sclerosis in the USA, Europe, Canada, Australia, and Brazil

Vasanthaprasad

Khurana²,

Vadapalle

et al. 2022

BMC Neurol

View full text Add to dashboard Cite

Background Secondary progressive multiple sclerosis (SPMS) is a subtype of multiple sclerosis (MS), which is a chronic neurological disease, characterised by inflammation of the central nervous system. Most of MS patients eventually progress to SPMS. This study estimates the prevalence of SPMS in the United States of America, Europe, Canada, Australia, and Brazil. Methods A systematic literature search of the Medline and Embase databases was performed using the OVID™ SP platform to identify MS epidemiological studies published in English from database inception to September 22, 2020. Studies reporting the prevalence of MS and proportion of SPMS patients in the included population were selected. The pooled prevalence of SPMS was calculated based on the proportion of SPMS patients. The Loney quality assessment checklist was used for quality grading. A meta-analysis of the proportions was conducted in RStudio. Results A total of 4754 articles were retrieved, and prevalence was calculated from 97 relevant studies. Overall, 86 medium- and high-quality studies were included in the meta-analysis. Most studies were conducted in European countries (84 studies). The estimated pooled prevalence of SPMS was 22.42 (99% confidence interval: 18.30, 26.95)/100,000. The prevalence of SPMS was more in the North European countries, highest in Sweden and lowest in Brazil. A decline in SPMS prevalence was observed since the availability of oral disease-modifying therapies. We also observed a regional variation of higher SPMS prevalence in urban areas compared with rural areas. Conclusion High variability was observed in the estimated SPMS prevalence, and the quality of the studies conducted. The influence of latitude and other factors known to affect overall MS prevalence did not fully explain the wide range of inter-country and intra-country variability identified in the results.

show abstract

“…A hiperatividade do detrusor é o diagnóstico mais frequente nas avaliações urodinâmicas [4], sendo observada em 44% a 81% dos pacientes.…”

Section: Introductionunclassified

Treinamento do assoalho pélvico com ou sem eletroterapia no tratamento dos sintomas da hiperatividade do detrusor em mulheres com esclerose múltipla e mielopatia associada ao HTLV-I (HAM/TSP): um ensaio clínico randomizado

Bottini¹,

Assis²,

Salgado³

et al. 2019

Fisioter Bras

View full text Add to dashboard Cite

Introdução: A esclerose múltipla (EM) é a mais comum das doenças desmielinizantes, caracterizada pela localização de múltiplas placas de desmielinização na substância branca encefálica e medular. A mielopatia associada ao HTLV-I (HAM/TSP) é uma doença neurodegenerativa progressiva cuja resposta imune é exacerbada. Objetivo: Avaliar o efeito da eletroterapia na musculatura do assoalho pélvico (MAP) sobre os sintomas hiperatividade detrusora em mulheres com EM e HTLV-1. Métodos: Ensaio clínico randomizado e controlado com 4 meses de acompanhamento, no qual 20 mulheres em estágio moderado de EM ou HTLV-1 submetidas a um programa de treinamento da MAP associado ou não à eletroterapia. As variáveis analisadas foram: sintomas de bexiga hiperativa (BH) pelo questionário validado OAB v8, contração perineal pelo esquema PERFECT e índice de qualidade de vida por meio do questionário Qualiveen. Divididas em dois grupos, grupo controle (G2) e grupo tratamento (G1) que foi submetido a um protocolo de treinamento da MAP, realizado duas vezes por semana por 20 sessões e após este período de tempo todas as mulheres foram reavaliadas. Resultados: Sob-homogeneidade inicial observada nas variáveis pessoais e clínicas, o protocolo a que o grupo tratamento (G1) foi submetido resultou na melhora da contração voluntária (p ≤ 0,001), teste de esforço (p ≤ 0,001), reflexo cutâneo-anal (p ≤ 0,001), força de contração (p ≤ 0,001), sustentação (p ≤ 0,001), contrações rápidas (p ≤ 0,001), contrações lentas (p ≤ 0,001) e nos sintomas de bexiga hiperativa (p ≤ 0,001), em relação à comparação inicial. Os resultados comprovam a eficácia de exercícios de fortalecimento da MAP acompanhados por um fisioterapeuta e o uso de correntes eletroterápicas de média frequência para o tratamento da BH na Esclerose Múltipla e na mielopatia associada ao HTLV-1. Conclusão: O protocolo de eletroestimulação mostrou-se benéfico em pacientes com EM e HTLV-1, promovendo melhora da BH e grau de contração perineal.Palavras-chave: bexiga hiperativa, modalidades de fisioterapia, assoalho pélvico.

show abstract

A systematic review about the epidemiology of primary progressive multiple sclerosis in Latin America and the Caribbean

Cited by 13 publications

References 46 publications

Societal costs of primary progressive multiple sclerosis in Australia and the economic impact of a hypothetical disease-modifying treatment that could delay disease progression

Societal costs of primary progressive multiple sclerosis in Australia and the economic impact of a hypothetical disease-modifying treatment that could delay disease progression

Systematic literature review and meta-analysis of the prevalence of secondary progressive multiple sclerosis in the USA, Europe, Canada, Australia, and Brazil

Treinamento do assoalho pélvico com ou sem eletroterapia no tratamento dos sintomas da hiperatividade do detrusor em mulheres com esclerose múltipla e mielopatia associada ao HTLV-I (HAM/TSP): um ensaio clínico randomizado

Contact Info

Product

Resources

About

A systematic review about the epidemiology of primary progressive multiple sclerosis in Latin America and the Caribbean

Cited by 13 publications

References 46 publications

Societal costs of primary progressive multiple sclerosis in Australia and the economic impact of a hypothetical disease-modifying treatment that could delay disease progression

Societal costs of primary progressive multiple sclerosis in Australia and the economic impact of a hypothetical disease-modifying treatment that could delay disease progression

Systematic literature review and meta-analysis of the prevalence of secondary progressive multiple sclerosis in the USA, Europe, Canada, Australia, and Brazil

Treinamento do assoalho pélvico com ou sem eletroterapia no tratamento dos sintomas da hiperatividade do detrusor em mulheres com esclerose múltipla e mielopatia associada ao HTLV-I (HAM/TSP): um ensaio clí­nico randomizado

Contact Info

Product

Resources

About

Treinamento do assoalho pélvico com ou sem eletroterapia no tratamento dos sintomas da hiperatividade do detrusor em mulheres com esclerose múltipla e mielopatia associada ao HTLV-I (HAM/TSP): um ensaio clínico randomizado